Table 3.
Immuno-histologic characteristics at the time of diagnosis.
| Variables | Overall | No Beta-Blockers | Cardio-Selective Beta-Blocker Users | Wide Spectrum Beta-Blocker Users | p-Value * | p-Value ** | p-Value ** |
|---|---|---|---|---|---|---|---|
| Intra tumor vessel density (n = 184) | 1.33 (±1.31, 1.04, 0.57–1.64) | 1.47 (±1.35, 1.17, 0.63–1.87) | 0.99 (±1.23, 0.68, 0.30–1.31) | 0.75 (±0.45, 0.63, 0.36–1.06) | 0.001 | 0.007 | 0.037 |
| KI67 (n = 174) | 14.3 (±10.3, 11.6, 6.6–20.0) | 14.9 (±10.3, 12.6, 7.6–20.8) | 14.0 (±10.6, 12.0, 7.0–19.0) | 8.46 (±8.5, 6.4, 4.5–8.5) | 0.028 | 0.947 | 0.021 |
| CD3 (n = 172) | 1306.4 (±1041.9, 1115.6, 478.2–1822.6) | 1204.1 (±981.7, 1047.8, 465.5–1717.0) | 1505.6 (±1251.0, 1278.7, 475.0–2102.8) | 1968.6 (±752.3, 1907.1, 1628.0–2332.0) | 0.016 | 0.524 | 0.015 |
| Granzyme B (n = 179) |
132.8 (±206.5, 61.4, 18.4–156.4) | 89.7 (±103.8, 52.3, 15.7–134.8) | 201.8 (±240.3, 104.4, 35.0–287.6) | 407.0 (±499.3, 220.9, 57.8–542.9) | 0.0006 | 0.043 | 0.003 |
| CD68 (n = 176) | 342.5 (±307.4, 261.3, 128.5–461.9) | 345.2 (±295.6, 275.8, 136.6–457.6) | 359.8 (±373.8, 208, 125.5–487.8) | 245.1 (±265.5, 154.7, 22.5–384.6) | 0.407 | - | - |
| MPO (n = 188) | 31.0 (±67.3, 9.9, 0.77–28.8) | 24.5 (±45.4, 9.6, 0–28.3) | 47.8 (±114.1, 10.0, 1.7–25.6) | 66.0 (±108.8, 17.3, 4.5–75.0) | 0.380 | - | - |
| CD34 + stromal fibroblasts (n = 175) |
4.56 (±3.49, 3.90, 1.92–5.82) | 5.00 (±3.54, 4.28, 2.39–6.63) | 3.59 (±3.25, 2.94, 1.31–4.59) | 2.36 (±2.09, 1.48, 0.87–3.46) | 0.001 | 0.036 | 0.009 |
| Inos (n = 163) | 381.2 (449.8, 256.9, 131.0–452.3) | 409.0 (±486.6, 268.6, 159.6–453.9) | 320.9 (±303.6, 215.8, 94.8–460.7) | 222.7 (±214.0, 111.2, 65.4–394.4) | 0.103 | - | - |
| IL10 (n = 147) | 195.0 (±207.3, 122.6, 39.7–296.0) | 184.5 (±191.9, 119.5, 48.2–235.5) | 184.6 (±268.7, 47.2, 26.2–296.0) | 339.1 (±183.6, 336.0, 201.0–435.0) | 0.0195 | 0.466 | 0.044 |
| TNFa (n = 148) | 191.1 (±251.8, 109.9, 42.5–225.8) | 163.4 (±225.2, 106.5, 41.6–181.3) | 223.4 (±232.0, 162.7, 65.5–256.1) | 416.7 (±416.5, 365.6, 23.4–692.8) | 0.086 | - | - |
| D240 (n = 194) | 0.23 (±0.30, 0.13, 0.05–0.29) | 0.25 (±0.32, 0.14, 0.05–0.33) | 0.17 (±0.22, 0.12, 0.02–0.23) | 0.13 (±0.12, 0.09, 0.06–0.14) | 0.220 | - | - |
| MHCII (n = 208) |
756.9, (±612.5, 648.1, 318.6–1012.3) | 752.8 (±627.4, 648.1, 290.2–1014.3) | 819.9 (±594.6, 703.2, 349.0–1072.7) | 640.9 (±492.5, 480.9, 360.4–912.8) | 0.593 | - | - |
| Mast cells (n = 185) |
179.6 (±129.4, 141.8, 96.0–238.9) | 162.6 (±107.1, 131.6, 89.1–208.9) | 269.6 (±188.3, 234.3, 133–402) | 147.6 (±92.3, 130.0, 88.0–205) | 0.004 | 0.003 | 0.985 |
Data are presented by mean (±SD, median, p25 and p75). * Comparisons were performed using Kruskal–Wallis non-parametric tests; ** with post-hoc analysis for the comparisons between cardioselective beta-blocker (BB) versus no BB and non-cardioselective BB versus no BB (Nemenyi test) when global p-value was <0.05. Data are presented by their mean (±SD, median, p25 and p75).